NRx Pharmaceuticals Dirección

Dirección controles de criterios 0/4

NRx Pharmaceuticals' El consejero delegado es Steve Willard , nombrado en Jul 2022, tiene un mandato de 1.42 años. la remuneración anual total es $1.07M , compuesta por 21.9% salario y 78.1% primas, incluidas acciones y opciones de la empresa. posee directamente 1.24% de las acciones de la empresa, por valor de $346.50K . La antigüedad media del equipo directivo y del consejo de administración es de 1.4 años y 2.6 años respectivamente.

Información clave

Steve Willard

Chief Executive Officer (CEO)

US$1.1m

Compensación total

Porcentaje del salario del CEO	21.9%
Permanencia del CEO	1.8yrs
Participación del CEO	1.1%
Permanencia media de la dirección	1.8yrs
Promedio de permanencia en la Junta Directiva	1.8yrs

Actualizaciones recientes de la dirección

Recent updates

Stephen Willard is the new CEO of NRx Pharmaceuticals

Jul 13

NRx Pharma fails to win FDA clearance for COVID therapy

Jul 01

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Steve Willard en comparación con los beneficios de NRx Pharmaceuticals?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	-US$30m
Sep 30 2023	n/a	n/a	-US$36m
Jun 30 2023	n/a	n/a	-US$39m
Mar 31 2023	n/a	n/a	-US$37m
Dec 31 2022	US$1m	US$234k	-US$40m

Compensación vs. Mercado: Steve($USD1.07M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD658.65K).

Compensación vs. Ingresos: Datos insuficientes para comparar la compensación de Steve con los resultados de la empresa.

CEO

Steve Willard (62 yo)

1.8yrs

Permanencia

US$1,067,186

Compensación

Mr. Stephen H. Willard, also known as Steve, Esq. serves as Acting Corporate Secretary at NRx Pharmaceuticals, Inc. He serves as Chief Executive Officer and Director at NRx Pharmaceuticals, Inc. since July...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jonathan Javitt	Co-Founder	less than a year	US$873.70k	15.54% $ 7.2m
Stephen Willard	Acting Corporate Secretary	1.8yrs	US$1.07m	1.1% $ 514.5k
Riccardo Panicucci	Chief Technology Officer	1.1yrs	US$240.00k	sin datos
Seth Van Voorhees	Treasurer	1.8yrs	US$534.84k	0.049% $ 22.7k
Richard Narido	Interim CFO	less than a year	sin datos	sin datos
Suzanne Messere	Investor Relations	no data	sin datos	sin datos
Philip Lavin	Chief Methodologist	no data	sin datos	sin datos
Dennis McBride	Chief Strategy Officer & Senior Scientist	6.5yrs	sin datos	sin datos
Matthew Duffy	Chief Business Officer	1.1yrs	sin datos	sin datos

1.8yrs

Permanencia media

62yo

Promedio de edad

Equipo directivo experimentado: NRXPEl equipo directivo de la empresa no se considera experimentado ( 1.4 años de permanencia media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Jonathan Javitt	Co-Founder	less than a year	US$873.70k	15.54% $ 7.2m
Stephen Willard	Acting Corporate Secretary	1.8yrs	US$1.07m	1.1% $ 514.5k
Chaim Hurvitz	Independent Director	2.9yrs	US$160.00k	2.33% $ 1.1m
Patrick Flynn	Independent Director	2.9yrs	US$180.00k	0.62% $ 289.3k
Janet Rehnquist	Director	less than a year	sin datos	sin datos

1.8yrs

Permanencia media

65yo

Promedio de edad

Junta con experiencia: NRXPno se consideran experimentados ( 2.6 años de permanencia media), lo que sugiere un nuevo consejo.

NRx Pharmaceuticals Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

Nrx Pharmaceuticals Announces Election of Janet Rehnquist to Its Board of Directors

NRx Pharmaceuticals, Inc., Annual General Meeting, Dec 19, 2023

NRX Pharmaceuticals, Inc. Appoints Richard Narido, as Principal Financial Officer and Principal Accounting Officer

Co-Founder recently bought US$64k worth of stock

CEO & Director recently bought US$59k worth of stock

Independent Director recently bought US$515k worth of stock

Recent updates

NRx Pharmaceuticals, Inc. Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)

NRx Pharmaceuticals, Inc. Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing

NRx Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 28, 2024

NRX Pharmaceuticals Announces Last Patient, Last Visit in Its Phase 2B/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression

New major risk - Share price stability

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.5 million.

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $1.5 million.

Panel Grants NRx Pharmaceuticals Request for an Exception to Nasdaq Listing Rules Until April 16, 2024, to Demonstrate Compliance with the Rule

NRx Pharmaceuticals, Inc. Announces Completion of Enrollment of Its Phase 2b/3 Trial of NRx-101 in Suicidal Treatment Resistant Bipolar Depression

NRx Pharmaceuticals, Inc. Announces FDA Qualified Infectious Disease Product and Fast Track Designation of NRX-101 in Complicated Urinary Tract Infection and Pyelonephritis

NRx Pharmaceuticals Demonstrates Compliance with Nasdaq MVLS Standard

Nrx Pharmaceuticals Announces Election of Janet Rehnquist to Its Board of Directors

Price target increased by 7.1% to US$3.75

NRx Pharmaceuticals, Inc. Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections

NRx Pharmaceuticals, Inc., Annual General Meeting, Dec 19, 2023

New major risk - Financial position

NRx Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 14, 2023

NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain

NRx Pharmaceuticals Receives Formal Notice from the Listing Qualifications Staff of Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

NRx Pharmaceuticals Announces Strategic Acceleration of its Plans to Develop Commercial Form of NRX-100 (intravenous ketamine) to Treat Acute Depression and Suicidality

NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain

NRX Pharmaceuticals, Inc. Appoints Richard Narido, as Principal Financial Officer and Principal Accounting Officer

NRx Pharmaceuticals, Inc. Announces New Data That Demonstrates Potent in Vitro Activity of NRx-101

NRx Pharmaceuticals Announces Submission of an Investigational New Drug Application for NRX -101 in the Treatment of Chronic Pain

NRx Pharmaceuticals, Inc. announced that it expects to receive $1.2 million in funding

Co-Founder recently bought US$64k worth of stock

New major risk - Share price stability

NRx Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 14, 2023

NRx Pharmaceuticals Receives Written Notification from Nasdaq Regarding Non-Compliance with Nasdaq Listing Rule 5450(b)(2)(A) – Market Value of Listed Securities

NRx Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $6.285501 million.

Price target increased by 7.7% to US$3.50

NRx Pharmaceuticals, Inc. Reports Minutes of U.S. Food and Drug Administration Meeting on Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality

NRx Pharmaceuticals, Inc. Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101

NRx Pharmaceuticals, Inc. Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted

Relief Therapeutics Holding AG (SWX:RLF) acquired ZYESAMI of NRx Pharmaceuticals, Inc.

CEO & Director recently bought US$59k worth of stock

Relief Therapeutics Holding AG and NRx Pharmaceuticals, Inc. Announces Close of Definitive Settlement Agreements

Independent Director recently bought US$515k worth of stock

High number of new and inexperienced directors

NRx Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

NRx Pharmaceuticals, Inc. Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process

NRx Pharmaceuticals, Inc. announced that it has received $10 million in funding

NRx Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 15, 2022

NRx Pharmaceuticals Receives Non-Compliance Letter from Nasdaq

NRx Pharmaceuticals, Inc. Announces the Appointment of Stephen Willard as its Chief Executive Officer

Stephen Willard is the new CEO of NRx Pharmaceuticals

Nrx Pharmaceuticals, Inc. Announces FDA Declines Emergency Use Authorization for Zyesami® (Aviptadil) for Subgroup of Patients with Critical Covid-19 At Immediate Risk of Death from Respiratory Failure Despite Treatment with Approved Therapy, Including Remdesivir

NRx Pharma fails to win FDA clearance for COVID therapy

High number of new and inexperienced directors

NRx Pharmaceuticals, Inc. Announces Class Action Suit Against the Company Dismissed

Nrx Pharmaceuticals, Inc. Announces Director Resignation

NRx Pharmaceuticals, Inc., Annual General Meeting, Jul 18, 2022

NRx Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Denied for aviptadil

NRx Pharmaceuticals, Inc. Provides Update on Breakthrough Therapy Designation Request for ZYESAMI® (Aviptadil)

NRx Pharmaceuticals Appoints Seth Van Voorhees as Chief Financial Officer, Effective June 13, 2022

Co-Founder recently bought US$58k worth of stock

NRx Pharmaceuticals, Inc. Announces Executive Changes

NRx Pharmaceuticals, Inc. Announces Data Safety Monitoring Board (DSMB) Update on U.S. National Institutes of Health (NIH) Study of ZYESAMI® (aviptadil) in Critical COVID-19

NRx Pharmaceuticals, Inc. Announces Enrollment of First Patient in Phase II Study of Bipolar Depression with Sub-Acute Suicidality

NRx Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

High number of new and inexperienced directors

NRx Pharmaceuticals, Inc. Files New Breakthrough Therapy Designation Request for ZYESAMI® (Aviptadil) in Subgroup of Patients with Critical COVID-19 with Respiratory Failure That Were Also Treated with Remdesivir and Continued to Progress

Quantum Leap Healthcare in Collaboration with NRx Pharmaceuticals Announce the Nebulized Form of ZYESAMI (Aviptadil), in the I-SPY COVID Trial of Critical COVID-19 Patients Stopped

NRx Pharmaceuticals, Inc. to Report Fiscal Year 2021 Results on Mar 31, 2022

Jonathan Javitt to Assume New Role as Chief Scientist of NRx Pharmaceuticals

Howard G. Smith Announces Securities Fraud Lawsuit Against NRx Pharmaceuticals, Inc

Análisis de compensación del CEO

CEO